Back to top
more

MannKind (MNKD)

(Delayed Data from NSDQ)

$7.44 USD

7.44
3,678,079

+0.18 (2.48%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $7.44 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

MannKind Corporation (MNKD) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings

by Zacks Equity Research

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Why MannKind (MNKD) Could Beat Earnings Estimates Again

by Zacks Equity Research

MannKind (MNKD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MannKind (MNKD) Just Overtook the 20-Day Moving Average

by Zacks Equity Research

When a stock breaks out above the 20-day simple moving average, good things could be on the horizon. How should investors react?

Is MannKind (MNKD) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how MannKind (MNKD) and Adagene Inc. Sponsored ADR (ADAG) have performed compared to their sector so far this year.

MannKind (MNKD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

Although the revenue and EPS for MannKind (MNKD) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

MannKind (MNKD) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 400% and 15.26%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

All You Need to Know About MannKind (MNKD) Rating Upgrade to Buy

by Zacks Equity Research

MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is MannKind (MNKD) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how MannKind (MNKD) and Merck (MRK) have performed compared to their sector so far this year.

MannKind Corporation (MNKD) Hit a 52 Week High, Can the Run Continue?

by Zacks Equity Research

MannKind (MNKD) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

MannKind (MNKD) Upgraded to Strong Buy: Here's Why

by Zacks Equity Research

MannKind (MNKD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Compared to Estimates, MannKind (MNKD) Q1 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 150% and 13.76%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Shattuck Labs, Inc. (STTK) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Shattuck Labs (STTK) delivered earnings and revenue surprises of 21.28% and 457.50%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Iovance Biotherapeutics (IOVA) Down 6.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's What Key Metrics Tell Us About MannKind (MNKD) Q4 Earnings

by Zacks Equity Research

The headline numbers for MannKind (MNKD) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

MannKind (MNKD) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 300% and 11.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MannKind (MNKD) Reports Q3 Earnings: What Key Metrics Have to Say

by Zacks Equity Research

While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Cytokinetics (CYTK) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Cytokinetics (CYTK) delivered earnings and revenue surprises of -87.50% and 98.47%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Biogen Inc. (BIIB) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

by Zacks Equity Research

Biogen Inc. (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's What Key Metrics Tell Us About MannKind (MNKD) Q2 Earnings

by Zacks Equity Research

While the top- and bottom-line numbers for MannKind (MNKD) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

MannKind (MNKD) Reports Break-Even Earnings for Q2

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 100% and 15.65%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Paratek Pharmaceuticals (PRTK) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Paratek (PRTK) delivered earnings and revenue surprises of 19.35% and 15.50%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

United Therapeutics (UTHR) Q2 Earnings & Sales Beat Estimates

by Zacks Equity Research

United Therapeutics' (UTHR) second-quarter 2023 earnings and sales beat estimates. Tyvaso sales continue to drive the company's top line.

MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

MannKind (MNKD) delivered earnings and revenue surprises of 20% and 8.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?